BioMarin Presented an Update on the Phase 1/2 Study of Valoctocogene Roxaparvovec at WFH's 2018 World Congress in Scotland

The following is an excerpt from a press release from BioMarin. Read the entire press release here.

BioMarin Pharmaceutical Inc. announced an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia A. The updated results were presented during an oral presentation at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland by John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and primary investigator for this Phase 1/2 study.
Previously, the company provided updated data on Dec. 9, 2017, at the American Society of Hematology (ASH) Annual Meeting.
The data presented at WFH is the most current data (Apr. 16, 2018 cut off) and includes 104 weeks of data.
 
Read the press release in its entirety here.